# Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

> **NCT02699099** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 699 (actual)

## Conditions studied

- Malaria
- Malaria Vaccines

## Interventions

- **DIETARY_SUPPLEMENT:** Vitamin A
- **BIOLOGICAL:** Candidate Plasmodium falciparum malaria vaccine
- **BIOLOGICAL:** MR-Vac
- **BIOLOGICAL:** Stamaril

## Key facts

- **NCT ID:** NCT02699099
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-10
- **Primary completion:** 2018-03-14
- **Final completion:** 2020-10-07
- **Target enrollment:** 699 (ACTUAL)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02699099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02699099, "Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02699099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*